Skip to main content

FY2025 Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Operating Results Summary

  • Net sales

    71,127 million yen

    YOY 10.9%

  • Operating profit

    5,834 million yen

    YOY 9.4%

  • Ordinary profit

    5,665 million yen

    YOY 10.9%

  • Profit attributable to owners of parent

    5,424 million yen

    YOY 6.3%

  • Earnings per share

    191.12 yen

    YOY 6.2%

The Group's consolidated net sales for the current fiscal year increased by 6,988 million yen compared to the same period of the previous fiscal year, reaching 71,127 million yen. This is mainly due to the strong and stable performance of the Pharmaceutical business, particularly in the obstetrics and gynecology area, as well as the consolidation of Ha Tay Pharmaceutical Joint Stock Company, a Vietnam-based pharmaceutical company that was previously an equity method investee. Furthermore, the cost of goods sold ratio increased by 0.9% YoY, and cost of sales amounted to 36,982 million yen, an increase of 4,178 million yen compared to the same period of the previous fiscal year. However, due to an increase in net sales, gross profit increased by 2,809 million yen YoY to 34,145 million yen. Selling, general and administrative expenses increased by 2,307 million yen from the same period of the previous fiscal year to 28,311 million yen, due to factors such as increased costs resulting from the progress of R&D. As a result, operating profit increased by 502 million yen YoY to 5,834 million yen. Ordinary profit amounted to 5,665 million yen, reflecting non operating income of 740 million yen and non-operating expenses of 908 million yen. In addition, the Company recorded gain on disposal of non-current assets of 96 million yen and gain on sale of investment securities of 1,474 million yen as extraordinary income, while recording loss on valuation of investment securities of 244 million yen as extraordinary loss. As a result, profit attributable to owners of parent increased 323 million yen from the same period of the previous year to 5,424 million yen.

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 14,515 29,255 45,332 58,927
Animal health business 1,841 3,765 5,759 7,334
Overseas business 1,226 2,133 3,240 4,640
Other businesses 58 99 153 225

(i) Pharmaceutical business

The Pharmaceutical business, which focuses on three therapeutic areas of internal medicine, obstetrics and gynecology, and urology, remained generally steady despite the impact of drug price revisions. Looking at individual products, in the obstetrics and gynecology field, sales of uterine fibroids and endometriosis agent "RELUMINA" grew to 11,173 million yen (up 6.1% YoY), while dysmenorrhea agent "DroEthi" launched in June 2022, also continued to grow to 8,312 million yen (up 10.8% YoY). In the internal medicine area, sales of flagship THYRADIN thyroid hormone preparation, increased 8.2% YoY to 8,775 million yen. Sales of poorly absorbable rifamycin antibiotic RIFXIMA also grew significantly, rising 22.1% YoY to 7,883 million yen, partly reflecting the impact of upward drug price revisions.

In the urology area, sales of LEUPRORELIN, an LH-RH derivative microcapsule-type sustained-release agent, amounted to 3,880 million yen, down 3.1% YoY.

As a result, net sales were 58,927 million yen (up 4.0% YoY), and segment profit was 7,121 million yen (up 12.1%

YoY).

(ii) Animal health business

Net sales from the Animal health business, covering veterinary pharmaceuticals, feed additives, and related products, increased to 7,334 million yen, up 1.2% YoY, mainly driven by strong performance of feed additives and veterinary pharmaceuticals. Segment profit rose to 344 million yen, up 14.7% YoY.

(iii) Overseas business

Following the consolidation of a Vietnam-based pharmaceutical company, Ha Tay Pharmaceutical Joint Stock Company, as a consolidated subsidiary in the previous fiscal year, the Company added a new reportable segment, "Overseas business." For Overseas business, net sales were 4,640 million yen and segment profit was 108 million yen.

(iv) Other businesses

In the Other businesses segment, which includes clinical testing services and medical devices, net sales were 225 million yen, down 5.2% YoY, and segment loss amounted to 13 million yen, compared with segment profit of 2 million yen in the same period last year.

Financial Position

Financial Position Summary

  • Total assets

    112,379 million yen

    YOY 7.8%

  • Net assets

    76,819 million yen

    YOY 7.0%

  • Equity ratio

    62.6 %

    YOY 0.0point

Overview of Financial Position

(Assets)

Consolidated total assets at the end of the current fiscal year increased by 8,084 million yen from the end of the previous fiscal year to 112,379 million yen. This was mainly due to an increase in investment securities, and accounts receivable despite a decrease in other intangible assets.

(Liabilities)

Consolidated total liabilities at the end of the current fiscal year increased by 3,079 million yen from the end of the previous fiscal year to 35,559 million yen. This was mainly due to increases in other in non-current liabilities and income taxes payable, while accounts payable decreased.

(Net assets)

Consolidated total net assets at the end of the current fiscal year increased by 5,004 million yen from the end of the previous fiscal year to 76,819 million yen. This was mainly due to an increase in retained earnings resulting from the recognition of profit attributable to owners of parent.

The equity ratio remained at 62.6%, unchanged from the end of the previous fiscal year.

Cash Flow Summary

  • Cash flows from operating activities

    6,303 million yen

  • Cash flows from investing activities

    (5,752) million yen

  • Cash flows from financing activities

    (818) million yen

  • Cash and cash equivalents at end of period

    10,126 million yen

Overview of Cash Flow Position

The balance of cash and cash equivalents (hereinafter referred to as "cash") at the end of the current fiscal year decreased by 476 million yen from the end of the previous fiscal year to 10,126 million yen.

The status of each cash flow and its contributing factors for the current fiscal year are as follows:

(Cash flows from operating activities)

The increase in net cash resulting from operating activities amounted to 6,303 million yen (an increase of 2,485 million yen from the same period of the previous year). This was mainly due to the recognition of profit before income taxes, despite an increase in inventories and a decrease in trade payables.

(Cash flows from investing activities)

The decrease in net cash resulting from investment activities amounted to 5,752 million yen (compared to a decrease of 6,124 million yen in the same period of the previous year). This mainly due to the acquisition of shares in affiliated companies, and property, plant and equipment, despite gains on sale of investment securities.

(Cash flows from financing activities)

The decrease in net cash resulting from financing activities amounted to 818 million yen (compared to a decrease of 2,956 million yen in the same period of the previous year). This is mainly due to the repayment of long-term borrowings and the payment of dividends.